Get the Daily Brief
Latest Biotech News
Bio‑Techne expands Oxford Nanopore partnership: long‑read kits for heritable disorder testing through 2032
Bio‑Techne and Oxford Nanopore extended and broadened their collaboration to develop and commercialize targeted enrichment long‑read sequencing kits for screening and diagnosing heritable genetic...
Novo Nordisk shuts cell therapy program – CEO reshuffle trims pipeline focus
Novo Nordisk informed Endpoints News it will discontinue its cell therapy research as part of a wider restructuring under CEO Maziar Mike Doustdar. The company—known for diabetes and obesity...
Trogenix nets $95 million – AAV ‘Trojan horse’ platform enters clinic planning
Edinburgh‑based Trogenix announced a $95 million Series A to advance its Odysseus platform—AAV vectors carrying Synthetic Super Enhancers that activate therapeutic payloads selectively in cancer...
Programmable promoter editing: DIAL enables heritable, tunable transgene control
Two papers published online in Nature Biotechnology introduce DIAL, a programmable promoter‑editing framework that engineers synthetic promoters to generate heritable setpoints of transgene...
Regeneron to seek FDA approval after NEJM hearing gains; Moderna posts melanoma responses
Regeneron said it will pursue regulatory approval after an NEJM‑published study showed its gene therapy restored usable hearing in most treated children with a congenital form of deafness. The...
Trogenix raises $95m – AAV 'Trojan horse' platform moves toward clinic
Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus platform and push its lead glioblastoma programme toward a planned first‑in‑human entry in early 2026. Investors on...
DIAL programmable promoters: tunable transgene control unveiled – CRISPR screens expose quiescent cell regulators
Researchers published a Nature Biotechnology study introducing DIAL (Dynamically Editable Artificial Loci), a programmable promoter‑editing framework that enables graded, reversible control of...
AI co‑pilots improve BCI control – minimally invasive, high‑res interface scales up
A study demonstrated that AI 'co‑pilots' can augment brain‑computer interface (BCI) control by sharing decoding responsibilities between algorithms and users, boosting accuracy and robustness in...
FAXP expands FFPE proteomics; plasma exosome profiling pins signatures in metastatic colorectal cancer
Researchers introduced Filter‑aided expansion proteomics (FAXP), a method that combines hydrogel tissue expansion with mass spectrometry to profile proteins in formalin‑fixed, paraffin‑embedded...
AI models predict neonatal growth risk and nephrotoxicity – clinical decision tools advance
Researchers applied machine learning to clinical and nutritional datasets to predict extrauterine growth restriction (EUGR) in preterm infants during transitional nutrition. The retrospective...
Aptamer‑enhanced monocytes and nobiletin nanoparticles show promise in neuroprotection and cognitive recovery
A preclinical study engineered monocytes with an aptamer enhancement to promote clearance of extracellular Tau and reduce neuroinflammation, reporting lower Tau burden and inflammatory markers in...
Ultrasound and circuit‑targeted stimulation refine non‑invasive brain therapies
Low‑intensity focused ultrasound (LIFU) studies showed the technique can modulate deep brain circuits with spatial precision, offering a non‑invasive modality for neuromodulation in movement,...
AI interpretable models speed protein engineering; sparse denoising advances structure generation
A team demonstrated how integrating interpretability into AI‑driven protein engineering workflows accelerates design cycles, enabling prioritized mutations with improved functional likelihood. The...
Start packaging early — four principles to avoid market delays; one‑day sterility testing for biopharma release
An industry primer urged early integration of packaging strategy across development phases, arguing that container‑closure systems, primary vs. secondary components, and regulatory testing plans...
Regeneron to FDA: Hearing-gene therapy posts clinical gains
Regeneron is advancing a gene therapy for a congenital form of deafness toward U.S. regulatory approval after clinical data showed substantial hearing improvement in children. New results...
Trogenix raises $95m: Trojan-horse AAV platform moves toward clinic
Edinburgh-based Trogenix closed a $95 million Series A co-led by IQ Capital to advance its Odysseus platform into human studies for aggressive solid tumors, the company said. Odysseus uses...
Mass production for CAR-iNK cells: Manufacturing bottleneck addressed
Researchers and companies disclosed a scalable manufacturing pathway for CAR-expressing induced natural killer (CAR-iNK) cells, aiming to lower cost and increase supply for off-the-shelf cell...
Next-gen engineered T cells: Platform advances expand therapeutic toolbox
A broad review of next-generation engineered T‑cell technologies outlines advances in receptor engineering, delivery modalities and safety switches designed to extend efficacy against solid...
FAXP: New proteomics method for FFPE tissue at cellular scale
Scientists introduced Filter-aided expansion proteomics (FAXP), a technique that combines hydrogel tissue expansion with mass spectrometry to analyze proteins in formalin-fixed, paraffin-embedded...
Plasma exosome proteomics identifies signals in metastatic colorectal cancer
A study profiled proteomes of plasma-derived exosomes from patients with metastatic colorectal cancer (mCRC) to identify candidate biomarkers for disease state and therapeutic response. The...